Elanco Animal Health Inc
ELAN
NYSE
Pharmaceuticals
$23.56
USD
-0.94 (-3.84%)
At close: Aug 20, 2026, 4:00 PM EDT
Market Cap $11.25B
Volume 4.6M
Revenue
$5.02B
TTM
+12.0%
YoY
Gross Margin
55%
TTM
+1.2%
YoY
Net Income
$-199.00M
TTM
-145.9%
YoY
Operating Cash Flow
$617.00M
TTM
+7.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1,241.0 | 1,137.0 | 1,144.0 | 1,371.0 | 1,368.0 |
YoY Growth | +4.8% | +10.4% | +12.2% | +14.9% | +10.2% |
Cost of Revenue | 528.0 | 530.0 | 555.0 | 586.0 | 570.0 |
Gross Profit | 713.0 | 607.0 | 589.0 | 785.0 | 798.0 |
Selling, General & Administrative | 400.0 | 351.0 | 338.0 | 381.0 | 449.0 |
Other Operating Expenses | 12.0 | 25.0 | 202.0 | 25.0 | 3.0 |
Total Operating Expenses | 640.0 | 605.0 | 772.0 | 641.0 | 683.0 |
Operating Income | 73.0 | 2.0 | -183.0 | 144.0 | 115.0 |
EBITDA | 243.0 | 203.0 | 193.0 | 332.0 | 295.0 |
Other Income / Expense | 0.0 | 0.0 | 4.0 | 0.0 | 0.0 |
Total Other Income / Expense | -48.0 | -52.0 | -76.0 | -57.0 | -59.0 |
Income Before Income Taxes | 25.0 | -50.0 | -259.0 | 87.0 | 56.0 |
Income Taxes | 14.0 | -16.0 | 17.0 | 30.0 | 2.0 |
Net Income | 11.0 | -34.0 | -276.0 | 57.0 | 54.0 |
Consolidated Net Income / Loss | 11.0 | -34.0 | -276.0 | 57.0 | 54.0 |
Net Income Attributable to Common Shareholders | 11.0 | -34.0 | -276.0 | 57.0 | 54.0 |
Basic EPS | $0.02 | -$0.07 | -$0.56 | $0.11 | $0.11 |
Diluted EPS | $0.02 | -$0.07 | -$0.56 | $0.11 | $0.11 |
Basic Shares Outstanding | 496.6M | 496.8M | 497.1M | 497.7M | 499.5M |
Diluted Shares Outstanding | 500.1M | 496.8M | 489.6M | 506.0M | 505.9M |